Introduction Parkinson's disease (PD) is the second most common neurodegenerative
disease after Alzheimer's disease. PD patients exhibit a classic spectrum of motor …

Abstract Parkinson's disease (PD), a neurodegenerative disorder, is traditionally classified
as a movement disorder. Patients typically suffer from many motor dysfunctions. Presently …

Abstract L-3, 4-dihydroxyphenylalanine (L-DOPA) was introduced about half a century ago
and is still the most effective medicine for the treatment of Parkinson's disease (PD) …

Parkinson's disease (PD) is a neurodegenerative movement disorder that is routinely treated
with levodopa. Unfortunately, long-term dopamine replacement therapy using levodopa …

Background Phosphodiesterase 10A is a member of the phosphodiesterase family whose
brain expression is restricted to the striatum. Phosphodiesterase 10A regulates cyclic …

Background: Tourette syndrome is a neurodevelopmental movement disorder involving
basal ganglia dysfunction. PDE10A inhibitors modulate signaling in the striatal basal …

One of the primary deficits in Parkinson's disease (PD) is the loss of dopaminergic neurons
in the substantia nigra pars compacta which leads to striatal dopaminergic deficits that …

Neural oscillatory changes within and across different frequency bands are thought to
underlie motor dysfunction in Parkinson's disease (PD) and may serve as biomarkers for …

Parkinson's disease (PD) is an increasingly prevalent neurodegenerative disorder with the
global burden of disease expected to double in the next few decades. L-3, 4 …

Résumé Cette thèse de doctorat s' intéresse aux effets bénéfiques de la neurostimulation
non-invasive du système corticomoteur dans la maladie de Parkinson (MP), chez des …